Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
GLMD Galmed Pharmaceuticals Ltd.Stock Price & Overview
$0.32
Charts
Quant Ranking
GLMD Analysis
GLMD News
Latest Headlines
Ratings Summary
People Also Follow
Similar to GLMD
ETFs Holding GLMD
GLMD Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
GLMD Revenue
GLMD Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
GLMD Ownership
GLMD Peers
Risk
Technicals
GLMD Transcripts
Investor Presentations
GLMD SEC Filings
Press Releases
GLMD Income Statement
GLMD Balance Sheet
GLMD Cash Flow Statement
GLMD Long Term Solvency
Discover More
You may be interested in: